Show simple item record

dc.contributor.authorTalaat, K.R.
dc.contributor.authorChen, W.H.
dc.contributor.authorMacLennan, C.A.
dc.contributor.authorKotloff, K.L.
dc.date.accessioned2019-12-25T18:07:10Z
dc.date.available2019-12-25T18:07:10Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85076303359&doi=10.1093%2fcid%2fciz892&partnerID=40&md5=4b46eafc3640abf66abf8326a266840f
dc.identifier.urihttp://hdl.handle.net/10713/11536
dc.description.abstractShigella causes morbidity and mortality worldwide, primarily affecting young children living in low-resource settings. It is also of great concern due to increasing antibiotic resistance, and is a priority organism for the World Health Organization. A Shigella vaccine would decrease the morbidity and mortality associated with shigellosis, improve child health, and decrease the need for antibiotics. Controlled human infection models (CHIMs) are useful tools in vaccine evaluation for early up- or down-selection of vaccine candidates and potentially useful in support of licensure. Over time, the methods employed in these models have become more uniform across sites performing CHIM trials, although some differences in conduct persist. In November 2017, a Shigella CHIM workshop was convened in Washington, District of Columbia. Investigators met to discuss multiple aspects of these studies, including study procedures, clinical and immunological endpoints, and shared experiences. This article serves as a uniform procedure by which to conduct Shigella CHIM studies. Copyright The Author(s) 2019.en_US
dc.description.sponsorshipThis supplement is sponsored by the Bill & Melinda Gates Foundation.en_US
dc.description.urihttps://doi.org/10.1093/cid/ciz892en_US
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical infectious diseases
dc.subjectShigellaen_US
dc.subjectchallenge studiesen_US
dc.subjectcontrolled human infection modelen_US
dc.subjecthuman infection studiesen_US
dc.subjectmethodsen_US
dc.titleConsensus Report on Shigella Controlled Human Infection Model: Conduct of Studiesen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/ciz892
dc.identifier.pmid31816068


This item appears in the following Collection(s)

Show simple item record